Dynavax Technologies Corporation

Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support!
Limited Premium Membership Offer
Choose a Plan, Save Money & Help Us Survive the Pandemic

Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

DVAX / Message Board / Read Message

BOARD

GROUPS

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

return to message board, top of board

Msg 1238 of 1779 at 10/1/2018 11:09:30 AM by

The following message was updated on 10/1/2018 12:14:08 PM.

Today's presentation at Cantor Fitzgerald Global Healthcare Conference

http://investors.dynavax.com/static-files/ae33dad3-741a-449b-a20a-e54801a731d4

At the presentation, Eddie mentioned that partner AstraZeneca just informed DVAX that top line data from AZD1419 result would be available later before the end of 2018 which confirmed AZD1419 trial was completed based on AZD1419 trial completion dates on 9/24/2018.

Apparently, DVAX contacted AstraZeneca right after AZD1419 estimated completion date...

e-mail to a friend

printer-friendly

add to library

| More

Recs: 2 Views: 282

return to message board, top of board

view thread Replies
Msg #	Subject	Author	Recs	Date Posted
1239	Re: Today's presentation at Cantor Fitzgerald Global Healthcare Conference	liuyiiv	2	10/1/2018 2:05:43 PM